Literature DB >> 6248563

Peripheral neuropathy and ophthalmologic toxicity after treatment with cis-dichlorodiaminoplatinum II.

R Becher, P Schütt, R Osieka, C G Schmidt.   

Abstract

A 57-year-old woman with inoperable bladder cancer received radiation treatment. Thirteen years later she relapsed at locoregional, retroperitoneal, and mediastinal sites. During treatment with cis-dichlorodiamineplatinum II (DDP) (30 mg/day for 5 days repeated every 4 weeks) she achieved a partial remission. After seven courses of DDP-chemotherapy she complained of numbness of her hands and legs and of diminished visual acuity of both eyes. After 4 weeks these symptoms grew less but intensified severely after another DDP-treatment. The temporal relationship of neurologic symptoms and their intensification by the last administration of DDP suggest this drug to be the causative agent for peripheral neuropathy and ophthalmologic toxicity.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6248563     DOI: 10.1007/bf00405506

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  5 in total

1.  Peripheral neuropathy as a complication of cis-dichlorodiammineplatinum(II) treatment: a case report.

Authors:  A Kedar; M E Cohen; A I Freeman
Journal:  Cancer Treat Rep       Date:  1978-05

2.  Effects of cis-diamminedichloroplatinum (NSC-119875) on hearing function in man.

Authors:  I J Piel; D Meyer; C P Perlia; V I Wolfe
Journal:  Cancer Chemother Rep       Date:  1974 Nov-Dec

3.  Refractory period in human sensory nerve fibres.

Authors:  W Tackmann; H J Lehmann
Journal:  Eur Neurol       Date:  1974       Impact factor: 1.710

4.  Cis-dichlorodiammineplatinum (II) (NSC-119875): hearing loss and other toxic effects in rhesus monkeys.

Authors:  S W Stadnicki; R W Fleischman; U Schaeppi; P Merriam
Journal:  Cancer Chemother Rep       Date:  1975 May-Jun

5.  Ophthalmologic toxicity after cis-dichlorodiammineplatinum(II) therapy.

Authors:  S Ostrow; D Hahn; P H Wiernik; R D Richards
Journal:  Cancer Treat Rep       Date:  1978-10
  5 in total
  8 in total

1.  Severe sensorimotor neuropathy after cisplatin therapy.

Authors:  M Pagès; A M Pagès; L Bories-Azeau
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-03       Impact factor: 10.154

2.  Transient blindness and seizure associated with cisplatin therapy.

Authors:  M T Cattaneo; V Filipazzi; E Piazza; E Damiani; G Mancarella
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

3.  Phase I study of oxaliplatin in patients with advanced cancer.

Authors:  J M Extra; M Espie; F Calvo; C Ferme; L Mignot; M Marty
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

4.  Chemotherapy of eyelid and peritorbital tumors.

Authors:  M N Luxenberg; T H Guthrie
Journal:  Trans Am Ophthalmol Soc       Date:  1985

5.  Cis-platinum chemotherapy for ocular basal cell carcinoma.

Authors:  M Morley; P T Finger; M Perlin; L R Weiselberg; D S DeBlasio
Journal:  Br J Ophthalmol       Date:  1991-07       Impact factor: 4.638

6.  Cisplatin neuropathy: clinical course and neurophysiological findings.

Authors:  M LoMonaco; M Milone; A P Batocchi; L Padua; D Restuccia; P Tonali
Journal:  J Neurol       Date:  1992-04       Impact factor: 4.849

Review 7.  The Protein-Binding Behavior of Platinum Anticancer Drugs in Blood Revealed by Mass Spectrometry.

Authors:  Jingchen Wang; Jianmei Tao; Shuailong Jia; Meiqin Wang; Hongliang Jiang; Zhifeng Du
Journal:  Pharmaceuticals (Basel)       Date:  2021-01-29

8.  Carboplatin-Induced Bilateral Papilledema: A Case Report.

Authors:  N Fischer; J Stuermer; B Rodic; M Pless
Journal:  Case Rep Oncol       Date:  2009-04-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.